NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities re...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2ec744b98cec42aba26d391463ce2a99 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:2ec744b98cec42aba26d391463ce2a99 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:2ec744b98cec42aba26d391463ce2a992021-12-02T12:30:12ZNAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion10.1038/s41598-017-02332-92045-2322https://doaj.org/article/2ec744b98cec42aba26d391463ce2a992017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02332-9https://doaj.org/toc/2045-2322Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities require binding and activation of the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor. However, after nearly 50 years of study, it remains unknown how AhR activation by dioxin produces toxic effects. Here, using the chick embryo close to hatching, a well-accepted model for dioxin toxicity, we identify NAD+ loss through PARP activation as a novel unifying mechanism for diverse effects of dioxin in vivo. We show that NAD+ loss is attributable to increased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 increased NAD+ levels and prevented both thymus atrophy and hepatosteatosis. Our findings additionally support a role for decreased NAD+ dependent Sirt6 activity in mediating dioxin toxicity following PARP activation. Strikingly, treatment in vivo with the NAD+ repleting agent nicotinamide, a form of vitamin B3, prevented thymus atrophy and hepatosteatosis by dioxin and increased sirtuin activity, providing a therapeutic approach for preventing dioxin toxicities in vivo.Silvia Diani-MooreJenny ShootsRubi SinghJoshua B. ZukArleen B. RifkindNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Silvia Diani-Moore Jenny Shoots Rubi Singh Joshua B. Zuk Arleen B. Rifkind NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
description |
Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities require binding and activation of the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor. However, after nearly 50 years of study, it remains unknown how AhR activation by dioxin produces toxic effects. Here, using the chick embryo close to hatching, a well-accepted model for dioxin toxicity, we identify NAD+ loss through PARP activation as a novel unifying mechanism for diverse effects of dioxin in vivo. We show that NAD+ loss is attributable to increased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 increased NAD+ levels and prevented both thymus atrophy and hepatosteatosis. Our findings additionally support a role for decreased NAD+ dependent Sirt6 activity in mediating dioxin toxicity following PARP activation. Strikingly, treatment in vivo with the NAD+ repleting agent nicotinamide, a form of vitamin B3, prevented thymus atrophy and hepatosteatosis by dioxin and increased sirtuin activity, providing a therapeutic approach for preventing dioxin toxicities in vivo. |
format |
article |
author |
Silvia Diani-Moore Jenny Shoots Rubi Singh Joshua B. Zuk Arleen B. Rifkind |
author_facet |
Silvia Diani-Moore Jenny Shoots Rubi Singh Joshua B. Zuk Arleen B. Rifkind |
author_sort |
Silvia Diani-Moore |
title |
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
title_short |
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
title_full |
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
title_fullStr |
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
title_full_unstemmed |
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion |
title_sort |
nad+ loss, a new player in ahr biology: prevention of thymus atrophy and hepatosteatosis by nad+ repletion |
publisher |
Nature Portfolio |
publishDate |
2017 |
url |
https://doaj.org/article/2ec744b98cec42aba26d391463ce2a99 |
work_keys_str_mv |
AT silviadianimoore nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion AT jennyshoots nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion AT rubisingh nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion AT joshuabzuk nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion AT arleenbrifkind nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion |
_version_ |
1718394388828127232 |